Publication:
Cytotoxicity of synthetic derivatives against breast cancer and multi-drug resistant breast cancer cell lines: a literature-based perspective study

dc.contributor.authorSharmin, Shabnam
dc.contributor.authorRahaman, Md Mizanur
dc.contributor.authorMartorell, Miquel
dc.contributor.authorSastre-Serra, Jorge
dc.contributor.authorSharif‑Rad, Javad
dc.contributor.authorButnariu, Monica
dc.contributor.authorBagiu, Iulia Cristina
dc.contributor.authorBagiu, Radu Vasile
dc.contributor.authorIslam, Mohammad Torequl
dc.date.accessioned2024-09-18T06:42:00Z
dc.date.available2024-09-18T06:42:00Z
dc.date.issued2021-11-20
dc.description.abstractCancer is the second most killer worldwide causing millions of people to lose their lives every year. In the case of women, breast cancer takes away the highest proportion of mortality rate than other cancers. Due to the mutation and resistance-building capacity of different breast cancer cell lines against conventional therapies, this death rate is on the verge of growth. New effective therapeutic compounds and treatment method is the best way to look out for in this critical time. For instance, new synthetic derivatives/ analogues synthesized from different compounds can be a ray of hope. Numerous synthetic compounds have been seen enhancing the apoptosis and autophagic pathway that directly exerts cytotoxicity towards different breast cancer cell lines. To cease the ever-growing resistance of multi-drug resistant cells against anti-breast cancer drugs (Doxorubicin, verapamil, tamoxifen) synthetic compounds may play a vital role by increasing effectivity, showing synergistic action. Many recent and previous studies have reported that synthetic derivatives hold potentials as an effective anti-breast cancer agent as they show great cytotoxicity towards cancer cells, thus can be used even vastly in the future in the field of breast cancer treatment. This review aims to identify the anti-breast cancer properties of several synthetic derivatives against different breast cancer and multi-drug-resistant breast cancer cell lines with their reported mechanism of action and effectivity.en
dc.format.number1es_ES
dc.format.page612es_ES
dc.format.volume21es_ES
dc.identifier.citationSharmin S, Rahaman MM, Martorell M, Sastre-Serra J, Sharifi-Rad J, Butnariu M, et al. Cytotoxicity of synthetic derivatives against breast cancer and multi-drug resistant breast cancer cell lines: a literature-based perspective study. Cancer Cell Int. 2021 Nov 20;21(1):612.en
dc.identifier.doi10.1186/s12935-021-02309-9
dc.identifier.e-issn1475-2867es_ES
dc.identifier.journalCancer Cell Internationales_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/19521
dc.identifier.pubmedID34801046es_ES
dc.identifier.puiL2014259466
dc.identifier.scopus2-s2.0-85119524975
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23146
dc.identifier.wos720725700002
dc.language.isoengen
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://dx.doi.org/10.1186/s12935-021-02309-9en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectSynthetic derivatives
dc.subjectBreast cancer cell line
dc.subjectMDR breast cancer cell line
dc.subjectCytotoxicity
dc.titleCytotoxicity of synthetic derivatives against breast cancer and multi-drug resistant breast cancer cell lines: a literature-based perspective studyen
dc.typereview articleen
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files